Prevalence of transmitted HIV drug resistance in Botswana: Lessons learned from the HIVDR-threshold survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey

AIDS Research and Human Retroviruses

Volumn 27, Issue 4, 2011, Pages 365-372

  Bussmann, Hermann ^a,b   De La Hoz Gomez, Florindo ^c   Roels, Thierry H ^d   Wester, C William ^a,b,e   Bodika, Stephane M ^d   Moyo, Sikhulile ^a   Taffa, Negussie ^d   Anderson, Marina G ^c   Mine, Madisa ^c   Bile, Ebi Celestin ^d   Yang, Chunfu ^f   Mphoyakgosi, Kereng ^c   Lehotzky, Erica Ann ^f   Mlotshwa, Busisiwe ^c   Mmelesi, Mpho ^c   Seipone, Khumo ^c   Makhema, Moeketsi J ^a   Marlink, Richard G ^a,b   Novitsky, Vladimir ^a,b   Essex, M ^a,b  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b Harvard AIDS Institute   (United States)

^c Department of HIV AIDS Prevention and Care   (Botswana)

^d Botswana United States of America (BOTUSA) Collaboration   (Botswana)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BOTSWANA; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MATERNAL AGE; NONHUMAN; PHYLOGENY; PRENATAL CARE; PRIMIGRAVIDA; PRIORITY JOURNAL; SENTINEL SURVEILLANCE; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; BOTSWANA; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; PREGNANCY; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 79953752235     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0299     Document Type: Article

References (56)

1. th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town. 19-22 July 2009. Abstract # WELBD105.
2. Egger M: Outcomes of ART in resource-limited and industrialized countries. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles. 25-28 February 2007. Abstract #62.
3. Bussmann H, Wester CW, Ndwapi N, et al.: Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008;22:2303-2311.
4. Stringer JS, Zulu I, Levy J, et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-793. (Pubitemid 44223102)
5. Coetzee D, Hildebrand K, Boulle A, et al.: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-895. (Pubitemid 38553709)
6. Weidle PJ, Malamba S, Mwebaze R, et al.: Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002;360:34-40. (Pubitemid 34756490)
7. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, and Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008;13:25-36. (Pubitemid 352019087)
8. Myatt M and Bennett DE: A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008;13:37-48. (Pubitemid 352019088)
9. Abegaz WE, Grossman Z, Wolday D, et al.: Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 2008;13:89-94. (Pubitemid 352019094)
10. Maphalala G, Okello V, Mndzebele S, et al.: Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008;13:95-100.
11. Pillay V, Ledwaba J, Hunt G, et al.: Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008;13:101-107.
12. Ndembi N, Lyagoba F, Nanteza B, et al.: Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retroviruses 2008;24:889-895. (Pubitemid 351871676)
13. Kamoto K and Aberle-Grasse J: Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008;13:83-87.
14. Somi GR, Kibuka T, Diallo K, et al.: Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008;13:77-82. (Pubitemid 352019092)
15. Aghokeng AF, Vergne L, Mpoudi-Ngole E, et al.: Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 2009;14:401-411.
16. National AIDS Coordinating Agency: Botswana AIDS impact survey (BAIS) II: Popular report. National AIDS Coordinating Agency, Gaborone, 2005.
17. Botswana Ministry of Health: Botswana 2007 sentinel surveillance protocol. Ministry of Health, Gaborone, 2008.
18. World Health Organization: Protocol for evaluation of transmitted HIV drug resistance using specimens from HIV sentinel serosurveys in resource-limited settings. WHO, Geneva, 2005.
19. McNulty A, Diallo K, Zhang J, et al.: Development and application of a broadly sensitive genotyping assay for surveillance of HIV-1 drug resistance in PEPFAR countries. Antivir Ther 2008,13:A117.
20. Gifford RJ, Liu TF, Rhee SY, et al.: The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009;25:1197-1198.
21. Edgar RC: MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004;32:1792-1797.
22. Los Alamos HIV sequence database. Los Alamos National Laboratory, Los Alamos, 2009. Available at http://www.hiv.lanl.gov.
23. Hall TA: BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999;41:95-98.
24. Posada D: jModelTest: Phylogenetic model averaging. Mol Biol Evol 2008;25:1253-1256.
25. Guindon S and Gascuel O: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 2003;52:696-704. (Pubitemid 37365050)
26. Tamura K, Dudley J, Nei M, and Kumar S: MEGA4: Molecular evolutionary genetics analysis (MEGA) software, version 4.0. Mol Biol Evol 2007;24:1596-1599. (Pubitemid 47236692)
27. Saitou N and Nei M: The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-425.
28. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980;16:111-120.
29. Felsenstein J: Confidence limits on phylogenies: An approach using the bootstrap. Evolution 1985;39:783-791.
30. Ray SC: SimPlot, version 2.5. 1999. Available at: http://sray.med.som. jhmi.edu/SCRoftware/ simplot/.
31. Parekh BS, Kennedy MS,Dobbs T, et al.: Quantitative detection of increasing HIV type 1 antibodies after seroconversion: A simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002;18:295-307. (Pubitemid 34253148)
32. Janssen RS, Satten GA, Stramer SL, et al.: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-48. (Pubitemid 28414995)
33. Botswana Ministry of Health: 2007 Botswana second generation HIV/AIDS surveillance technical report. Ministry of Health, Gaborone, 2008.
34. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009;4:e4724.
35. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223. (Pubitemid 46036930)
36. Vardavas R and Blower S: The emergence of HIV transmitted resistance in Botswana: "When will the WHO detection threshold be exceeded?" PLoS ONE 2007;2:e152.
37. Armstrong KL, Lee TH, and Essex M: Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1. J Virol 2009;83:4051-4059.
38. Little SJ, Frost ST, Wong JK, et al.: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82:5510-5518. (Pubitemid 351705258)
39. Weinstock HS, Zaidi I, Heneine W, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004;189:2174-2180. (Pubitemid 38757188)
40. Murphy G and Parry JV: Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 2008;13:pii=18966.
41. Guy R, Gold J, Calleja JM, et al.: Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: A systematic review. Lancet Infect Dis 2009;9:747-759.
42. Marinda ET, Hargrove J, Preiser W, et al.: Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 2010;53:496-499.
43. Sakarovitch C, Rouet F, Murphy G, et al.: Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr 2007;45:115-122.
44. Kothe D, Byers RH, Caudill SP, et al.: Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr 2003;33:625-634. (Pubitemid 36975851)
45. Gupta SB, Murphy G, Koenig E, et al.: Comparison of methods to detect recent HIV type 1 infection in cross-sectionally collected specimens from a cohort of female sex workers in the Dominican Republic. AIDS Res Hum Retroviruses 2007;23:1475-1480.
46. Novitsky V, Woldegabriel E, Kebaabetswe L, et al.: Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. J Acquir Immune Defic Syndr 2009;50:65-76.
47. Fisher M, Pao D, Murphy G, et al.: Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS 2007;21:2309-2314. (Pubitemid 350287457)
48. McDougal JS, Parekh BS, and Peterson ML: Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006;22:945-952. (Pubitemid 46100678)
49. Hargrove JW, Humphrey JH, Mutasa K, et al.: Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 2008;22:511-518. (Pubitemid 351317293)
50. Hallett TB, Ghys P, Bärnighausen T, Yan P, and Garnett GP. Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One 2009;4:e5720.
51. Novitsky V, Wang R, Kebaabetswe L, et al.: Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. J Acquir Immune Defic Syndr 2009;52:265-272.
52. Laeyendecker O, Oliver A, Astemborski J, et al.: Improved precision of cross-sectional HIV incidence testing using a multi-assay algorithm that includes BED and an avidity assay with modified assay cut-offs. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco. 16-19 February 2010. Abstract #935.
53. Braunstein S, Nash D, Ingabire C, et al.: Performance of BED-CEIA and avidity index assays in a sample of ART-naïve, female sex workers in Kigali, Rwanda. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco. 16-19 February 2010. Abstract #939.
54. Bussmann H, de la Hoz Omez F, Roels TH, et al.: Prevalence of transmitted HIV drug resistance in Botswana: Lessons learned from the HIVDR-TS conducted during the 2005 Botswana sentinel survey. 4th Conference on HIV Pathogenesis and Treatment and Prevention. Sydney. 22-25 July 2007. Abstract #TUPEB041.
55. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-929. (Pubitemid 30177052)
56. Porco TC, Martin JN, Page-Shafer KA, et al.: Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004;18:81-88. (Pubitemid 38402321)